Astellas Pharma Inc.(4503) Summary

Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.

Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.